Micro-abnormalities in the retina and choroid induced by anti-CTLA4 treatment.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 04 2023
18 04 2023
Historique:
received:
11
08
2022
accepted:
14
04
2023
medline:
20
4
2023
pubmed:
19
4
2023
entrez:
18
04
2023
Statut:
epublish
Résumé
Anti-Cytotoxic T-Lymphocyte Associated protein 4 agents, such as ipilimumab, are widely applied to various cancers. However, they cause immune-related adverse effects throughout the body, including the eye. This study examined whether ipilimumab induces retinal and choroidal abnormalities in rodents, and investigated potential underlying mechanisms. Female wild-type mice were injected with ipilimumab three times/week for 5 weeks. The mice underwent optical coherence tomography (OCT) on the first day of the 6th week. Retinal function and morphology were evaluated by light microscopy, immunohistochemistry and electroretinography (ERG). On OCT, the lines indicating the ellipsoid and interdigitation were obscure in treated mice, suggesting outer retina destruction. Haematoxylin-eosin staining revealed destruction, shortening, and outer segment vacuolization. Treated mice exhibited weaker, fragmented rhodamine peanut agglutinin staining in outer photoreceptor structures. The choroid of treated mice showed severe infiltration of CD45-positive cells. In addition, CD8-positive cells invaded into the outer retina. On ERG, rod, maximum responses of combined rods and cones, and cone response wave amplitudes were significantly reduced in treated mice. Ipilimumab may induce impairments in outer photoreceptor architecture accompanied with CD8- positive infiltration in the retina and CD45-positive cell infiltration in the choroid, which may contribute to retinal function deterioration.
Identifiants
pubmed: 37072549
doi: 10.1038/s41598-023-33582-5
pii: 10.1038/s41598-023-33582-5
pmc: PMC10113220
doi:
Substances chimiques
Ipilimumab
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6309Informations de copyright
© 2023. The Author(s).
Références
JAMA Ophthalmol. 2016 Mar;134(3):343-5
pubmed: 26746681
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Am J Ophthalmol. 2009 Dec;148(6):939-45.e3
pubmed: 19781687
J Immunother. 2004 Nov-Dec;27(6):478-9
pubmed: 15534492
Can J Ophthalmol. 2015 Feb;50(1):e2-4
pubmed: 25677296
J Immunother. 2015 Feb-Mar;38(2):80-4
pubmed: 25658618
Jpn J Ophthalmol. 2004 May-Jun;48(3):222-7
pubmed: 15175913
Retin Cases Brief Rep. 2012 Fall;6(4):423-6
pubmed: 25389947
Indian J Ophthalmol. 2019 Jul;67(7):1217-1219
pubmed: 31238472
Retina. 2018 Jun;38(6):1063-1078
pubmed: 29689030
Arq Bras Oftalmol. 2006 Nov-Dec;69(6):895-906
pubmed: 17273686
Exp Eye Res. 2005 Feb;80(2):273-80
pubmed: 15670805
Lancet. 2021 Sep 11;398(10304):1002-1014
pubmed: 34509219
Sci Transl Med. 2014 Apr 2;6(230):230ra45
pubmed: 24695685
Int Med Case Rep J. 2019 Nov 19;12:355-361
pubmed: 31819668
Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2285-2295
pubmed: 31440820
BMC Ophthalmol. 2020 Jun 8;20(1):221
pubmed: 32513129